View in EDS

Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.

Saved in:
Bibliographic Details
Title: Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Authors: Morgan RD; Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK., Banerjee S; The Royal Marsden NHS Foundation Trust, London, UK., Hall M; Mount Vernon Cancer Centre, Northwood, Middlesex, UK., Clamp AR; Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK., Zhou C; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, UK., Hasan J; Christie NHS Foundation Trust, Manchester, UK., Orbegoso C; The Royal Marsden NHS Foundation Trust, London, UK., Taylor S; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, UK., Tugwood J; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, UK., Lyon AR; Royal Brompton and Harefield NHS Foundation Trust, London, UK; Faculty of Medicine, National Heart & Lung Institute, Imperial College London, London, UK., Dive C; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, Manchester, UK., Rustin GJS; Mount Vernon Cancer Centre, Northwood, Middlesex, UK., Jayson GC; Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. Electronic address: Gordon.Jayson@christie.nhs.uk.
Source: Gynecologic oncology [Gynecol Oncol] 2020 Mar; Vol. 156 (3), pp. 545-551. Date of Electronic Publication: 2020 Jan 10.
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1095-6859
DOI:10.1016/j.ygyno.2020.01.005